Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
TECHNETIUM TC 99M MPI MDP is a radiopharmaceutical diagnostic imaging agent administered by injection, developed by GE HealthCare. The agent is used for myocardial perfusion imaging (MPI) and bone imaging to assess cardiac viability and skeletal pathology. It functions as a radiotracer that accumulates in target tissues, allowing visualization via nuclear medicine imaging.
With LOE approaching and moderate competitive pressure (30/100), commercial teams face revenue defense challenges and likely workforce optimization within the next 2–3 years.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TECHNETIUM TC 99M MPI MDP offers stable but contracting career opportunities, as the product enters LOE with zero linked job openings currently. Roles focus on revenue defense and transition management rather than growth initiatives, limiting long-term advancement potential on this specific asset.
Worked on TECHNETIUM TC 99M MPI MDP at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.